GPX4 upregulation induced by the activation of erb-b2 receptor tyrosine kinase 2 (HER2 or ERBB2) pathway may contribute to ferroptosis resistance in luminal breast cancer cell lines[104]. This evidence concerns the gene ERBB2 and breast carcinoma.